Half-year report · Q2
2342.TEDINET S100UI5X
Period2024-04-01 → 2024-09-30
Filed2024-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥6.3bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥13.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥6.4bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | −¥111m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | ¥89m | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | −¥157m | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥108m | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥95m | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | −¥195m | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥94m | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥182m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥48m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥185m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | ¥42m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥10.6bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥9.8bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥10.5bn | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥4.8bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥3.8bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥5.8bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥6.0bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥6.1bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.3bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.5bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.2bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.5bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.9bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.5bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥421m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥392m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥366m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥175m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥281m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥129m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥379m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥343m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥47m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-10.97 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥0.24 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥2.87 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 53.5% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.1% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 57.4% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 31
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥3m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥3m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥114m |
| jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥806m |
| jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥803m |
| jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥3m |
| jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥189m |
| jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥5.5bn |
| jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥5.5bn |
| jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥45,000 |
| jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥192m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥6.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥6.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥3m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥3m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥3m |
| Reconciling Itemsreconciling | revenue external | 2023-04-01 → 2023-09-30 | ¥450,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥4m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥108m |
| jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥981m |
| jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥978m |
| jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥3m |
| jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥27m |
| jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥5.4bn |
| jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥5.4bn |
| jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥628,000 |
| jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥223m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥6.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥6.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥4m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥196m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 501
| Item | Context | Value | Unit |
|---|---|---|---|
| Provision for bonuses sga | Prior1YTDDuration | 32008000 | JPY |
| Provision for bonuses sga | CurrentYTDDuration | 43424000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E05317-000DrugDiscoverySupportBusinessReportableSegmentsMember | 978447000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E05317-000InvestmentsAndConsultingBusinessReportableSegmentsMember | 5398402000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 6376849000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | 450000 | JPY |
| Revenues from external customers | Prior1YTDDuration | 6377299000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E05317-000DrugDiscoverySupportBusinessReportableSegmentsMember | 3000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E05317-000InvestmentsAndConsultingBusinessReportableSegmentsMember | 628000 | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 3628000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -3628000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E05317-000DrugDiscoverySupportBusinessReportableSegmentsMember | 981447000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E05317-000InvestmentsAndConsultingBusinessReportableSegmentsMember | 5399031000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 6380478000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -3178000 | JPY |
| Net sales | Prior1YTDDuration | 6377299000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E05317-000DrugDiscoverySupportBusinessReportableSegmentsMember | -26609000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E05317-000InvestmentsAndConsultingBusinessReportableSegmentsMember | 223077000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 196468000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | -107944000 | JPY |
| Operating income | Prior1YTDDuration | 88523000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E05317-000DrugDiscoverySupportBusinessReportableSegmentsMember | 803128000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E05317-000InvestmentsAndConsultingBusinessReportableSegmentsMember | 5508752000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 6311881000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 6311881000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E05317-000DrugDiscoverySupportBusinessReportableSegmentsMember | 3000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E05317-000InvestmentsAndConsultingBusinessReportableSegmentsMember | 45000 | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 3045000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -3045000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E05317-000DrugDiscoverySupportBusinessReportableSegmentsMember | 806128000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E05317-000InvestmentsAndConsultingBusinessReportableSegmentsMember | 5508798000 | JPY |
| Net sales | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 6314926000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -3045000 | JPY |
| Net sales | CurrentYTDDuration | 6311881000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E05317-000DrugDiscoverySupportBusinessReportableSegmentsMember | -188669000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E05317-000InvestmentsAndConsultingBusinessReportableSegmentsMember | 191717000 | JPY |
| Operating income | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 3048000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | -113817000 | JPY |
| Operating income | CurrentYTDDuration | -110769000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)福岡財務支局長 | |
| Filing date cover page | FilingDateInstant | 2024-11-13 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第27期中（自 2024年４月１日 至 2024年９月30日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)株式会社トランスジェニックグループ（旧会社名 株式会社トランスジェニック） | |
| Company name in english cover page | FilingDateInstant | Text · Plus | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 福永 健司 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |